Surgical outcomes in patients with haemophilia A or B receiving extended half‐life recombinant factor VIII and IX Fc fusion proteins: Real‐world experience in the Nordic countries

INTRODUCTION: Perioperative dosing recommendations vary across Nordic haemophilia treatment centres (HTCs) for extended half‐life (EHL) factor concentrates in haemophilia A/B (HA/HB) patients. AIM: To summarise Nordic real‐world surgical experiences with EHL recombinant factor VIII/IX Fc (rFVIIIFc/r...

Descripción completa

Detalles Bibliográficos
Autores principales: Lehtinen, Anna‐Elina, Baghaei, Fariba, Astermark, Jan, Holme, Pål André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542088/
https://www.ncbi.nlm.nih.gov/pubmed/35575446
http://dx.doi.org/10.1111/hae.14585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542088/
https://www.ncbi.nlm.nih.gov/pubmed/35575446
http://dx.doi.org/10.1111/hae.14585

Ejemplares similares